贝伐单抗联合顺铂化疗对恶性黑色素瘤的疗效分析  

Treatment Effect and Prognosis of Bevacizumab Combined with Cisplatin for Treatment of Malignant Melanoma Patients

作　　者：姜宏[1] 池晓峰[1] 杨东[1] 刘洪波[1] 梁衍涛[1] JIANG Hong;CHI Xiaofeng;YANG Dong;LIU Hongbo;LIANG Yantao(Department of Bone and Soft Tissue Oncology, Jilin Cancer Hospital, Changchun, Jilin, 130012, China)

机构地区：[1]吉林省肿瘤医院骨及软组织肿瘤科,吉林长春130012

出　　处：《肿瘤药学》2017年第6期752-755,768,共5页Anti-Tumor Pharmacy

基　　金：吉林省科技厅发展计划项目资助课题(20140101170JC)

摘　　要：目的探讨贝伐单抗联合顺铂化疗对恶性黑色素瘤的疗效及预后影响。方法 2011年7月~2015年1月间在本院接受治疗的晚期恶性黑色素瘤患者70例,回顾治疗方案并分为接受顺铂常规化疗的对照组36例、接受贝伐单抗联合联合顺铂化疗的观察组34例。评估两组患者的近期疗效,对比血清血管新生指标、预后相关指标含量的差异。随访2年并记录1年、2年生存率和平均生存时间。结果观察组治疗总有效率显著高于对照组(P<0.05)。观察组治疗后血清血管新生指标内皮生长因子(VEGF)、胰岛素生长因子-1(IGF-1)、基质金属蛋白酶-9(MMP-9)和预后相关指标S-100B蛋白(S-100B)、乳酸脱氢酶(LDH)的含量均显著低于对照组(P<0.05)。随访期内,观察组患者的1年、2年生存率高于对照组,平均生存时间长于对照组,差异均有统计学意义(P<0.05)。结论贝伐单抗联合顺铂化疗可显著提高晚期恶性黑色素瘤患者的近期疗效,抑制肿瘤血管新生,同时优化远期治疗结局。Objective To study the treatment effect of bevacizumab combined with cisplatin on malignant melanoma patients and their influence in prognosis.Methods70advanced malignant melanoma patients were chosen as research subjectsin our hospital during July2011to January2015,treatment schemes were reviewed and they were divided into control group(n=36)undergoing conventional cisplatin chemotherapy and observation group(n=34)undergoing bevacizumab combined with cisplatin chemotherapy.Short-term efficacy of the patients in the two groups were evacuated and serum contents of angiogenesis and prognosis were measured.2years were followed up,1-year survival rate,2-year survival rate and average survival time were recorded.Results Total effective rate of patients in observation group was significantly higher than that in control group(P<0.05).Serum contents of VEGF,IGF-1and MMP-9of patients in observation group after treatment were lower than those in control group,prognostic indicators such as S-100B and LDH of patients in observation group after treatment were lower than those in control group(P<0.05).During the follow-up period,1-year survival rate,2-year survival rate and the survival rate of the patients in the observation group were higher than those in the control group,and average survival time of the patients in the observation group was longer than that in control group(P<0.05).Conclusion Bevacizumab combined with cisplatin chemotherapy can significantly improve the short-term outcome of patients with advanced malignant melanoma,inhibit tumor angiogenesis,and optimize the long-term outcome of treatment.

关 键 词：恶性黑色素瘤 贝伐单抗 顺铂 血管新生 预后 

分 类 号：R739.5[医药卫生—肿瘤]